Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic
Pharmaceutical Technology
NOVEMBER 24, 2022
Study designs can be conventional, hybrid, or tracer studies, which can all generate the required data and be suitable to form part of the eventual regulatory submission data package. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.
Let's personalize your content